adverse events

You have access
Usefulness of Implementing Comprehensive Pharmaceutical Care for Metastatic Renal Cell Carcinoma Outpatients Treated with Pazopanib
MAKI TODO, SUGURU SHIROTAKE, KOSHIRO NISHIMOTO, YOTA YASUMIZU, GOU KANEKO, HIDEYUKI KONDO, TAKASHI OKABE, HIDEKI MAKABE and MASAFUMI OYAMA

Anticancer Research February 2019, 39 (2) 999-1004; DOI: https://doi.org/10.21873/anticanres.13205
You have access
Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia
SUSAN K. WOELICH, JAMES T. BRAUN, MARTIN W. SCHOEN, RESHMA RAMLAL, CARL E. FRETER, PAUL J. PETRUSKA and JACK M. LIONBERGER

Anticancer Research February 2017, 37 (2) 713-717;
You have access
Reduced Dose of Salvage-line Regorafenib Monotherapy for Metastatic Colorectal Cancer in Japan
GEN HIRANO, AKITAKA MAKIYAMA, CHINATSU MAKIYAMA, TAITO ESAKI, HISANOBU ODA, KEITA UCHINO, MASATO KOMODA, RISA TANAKA, YUZO MATSUSHITA, KENJI MITSUGI, YOSHIHIRO SHIBATA, HOZUMI KUMAGAI, SHUJI ARITA, HIROSHI ARIYAMA, HITOSHI KUSABA, KOICHI AKASHI and EISHI BABA

Anticancer Research January 2015, 35 (1) 371-377;
You have access
Prospective Evaluation of Safety of Immune-cell Therapy for Patients with Various Types of Advanced Cancer
TAKASHI KAMIGAKI, ERIKO MATSUDA, SACHIKO OKADA, KEIKO NAITOH, TAKASHIGE KONDO, HIROSHI IBE, RYUJI MAEKAWA and SHIGENORI GOTO

Anticancer Research August 2014, 34 (8) 4601-4607;
You have access
Analysis of Adverse Events of Bevacizumab-containing Systemic Chemotherapy for Metastatic Colorectal Cancer in Japan
TAICHI ISOBE, KEITA UCHINO, CHINATSU MAKIYAMA, HIROSHI ARIYAMA, SHUJI ARITA, SHINGO TAMURA, MASATO KOMODA, HITOSHI KUSABA, TSUYOSHI SHIRAKAWA, TAITO ESAKI, KENJI MITSUGI, SHIGEO TAKAISHI, KOICHI AKASHI and EISHI BABA

Anticancer Research April 2014, 34 (4) 2035-2040;
You have access
Management of Adverse Events in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib and Clinical Outcomes
MAKI ARAKAWA-TODO, TAKAHIKO YOSHIZAWA, KENJI ZENNAMI, GENYA NISHIKAWA, YOSHIHARU KATO, IKUO KOBAYASHI, KEISHI KAJIKAWA, YOSHIAKI YAMADA, KATSUHIKO MATSUURA, IKUTO TSUKIYAMA, HIROKO SAITO, TAKAAKI HASEGAWA, KOGENTA NAKAMURA and MAKOTO SUMITOMO

Anticancer Research November 2013, 33 (11) 5043-5050;
You have access
Clinical Significance of Erlotinib Monotherapy for Gefitinib-resistant Non-small Cell Lung Cancer with EGFR Mutations
NOBUYUKI KOYAMA and YOSHITAKA UCHIDA

Anticancer Research November 2013, 33 (11) 5083-5089;

Main menu

User menu

Search

adverse events

Pages